AUS
NZ
UK
CA
USA
IND
Highlights
- Percheron secures global rights to promising cancer immunotherapy asset.
- Plans underway for Phase II trial of HMBD-002 by 2026.
- Deal includes up to US$287M in milestones plus royalties.
Percheron Therapeutics (ASX:PER) has taken a strategic leap forward with a new global licensing agreement, acquiring exclusive rights to the clinical-stage monoclonal antibody HMBD-002 from Hummingbird Bioscience. This agreement repositions the biotech player within the therapeutic development landscape, especially in the realm of immune checkpoint inhibitors.
A Strategic Licensing Deal
Under the terms of the deal, Percheron will make an upfront payment of US$3 million (AU$4.6 million), with potential milestone payments amounting to US$287 million (AU$443 million). Additionally, the agreement includes royalties tied to future net sales. HMBD-002 targets VISTA (V-domain Ig suppressor of T cell activation), a known immunosuppressive protein frequently associated with poor clinical outcomes in cancer. This mechanism positions HMBD-002 as a compelling candidate within the immuno-oncology space.
The asset has already completed a Phase I trial in the United States, where it exhibited both promising pharmacological activity and a favourable safety profile. With this early data in hand, Percheron is now mapping its development course. The company plans to initiate a Phase II clinical trial in calendar year 2026, following additional consultations with regulatory authorities and clinical experts to solidify its approach.
Clinical-Stage Return for Percheron
The licensing marks a pivotal moment for Percheron as it regains momentum in the mid-clinical-stage development category. The company aims to address critical gaps in treatment by advancing assets that can target unmet needs in immunotherapy-resistant cancers.
HMBD-002's entry into Percheron’s portfolio brings new energy to the firm’s pipeline and helps recalibrate its strategic focus. The leadership at both Percheron and Hummingbird expressed confidence in the future of this asset, with Hummingbird’s CEO remarking on the potential of the therapy and the strength of Percheron’s team to bring it forward.
Market Position and ASX200 Landscape
Although Percheron is not currently a constituent of the S&P/ASX 200 index, its latest move draws renewed attention from the biotech investment community. For investors and market watchers tracking innovation in the life sciences segment of the S&P/ASX 200, Percheron's development strategy reflects broader momentum within Australia’s biotechnology sector.
This deal signals not just a revival for Percheron, but also reaffirms the growing clinical appetite for therapies that address immune escape pathways like VISTA, which remain a challenging frontier in cancer care.
